Wis Medical develops ultra-thin, lightweight wearable patch system that enable at-home sleep diagnostics comparable to in-lab polysomnography. Our Tedream™ patch integrates multimodal signals with AI-driven analysis, enhancing patient care, accessibility, and clinical efficiency.
UWICOM Co., Ltd.
UWICOM is a healthcare technology company based in South Korea, specializing in developing innovative assistive listening devices to improve communication and quality of life for the elderly. Certified with KC, CE, FCC, and TELEC, and supported by registered patents, our solutions meet international safety and performance standards.
STANDPACK
Standpack está comprometido con líderes mundiales en el campo del embalaje especial y con la producción de productos de la más alta calidad. Basados en la tecnología patentada y en los conocimientos prácticos recogidos a lo largo de los años, ofrecemos formas de maximizar la promoción de ventas para nuestros clientes más bien sólo vendiendo productos. Además, a través de la I+D continuas, estamos trabajando duro para desarrollar aplicaciones de patentes y materiales de embalaje funcionales para mantener el ritmo con las tendencias cambiantes del mercado y las NEEDS de los clientes. Avanzando, seguiremos construyendo la confianza de los clientes a través del desarrollo continuo de la tecnología y el control de calidad, y nos esforzaremos por proporcionar satisfacción a los clientes.
RF MORECOM INNOVATION
We are a premium lighting company redefining the relationship between technology, people, and nature. Using next-generation QD-LED with near-infrared light, we create solutions for human wellness, pet health, and smart farming. Through innovation and collaboration, we deliver lighting that enhances life, balance, and care.
REV-MED Inc.
We exist to extend life and overcome disease. REV-MED is a leading biotech company specializing in Autologous Stem Cell Therapy, TriCell PRP (Platelet-Rich Plasma), and Novastem BMAC (Bone Marrow Stem Cell Concentration). Our mission is clear: to enhance the body’s natural ability to heal, restore, and regenerate—so people can live longer, healthier lives. By focusing on autologous, cell-based regenerative therapies, we deliver precision-engineered solutions that cover the full spectrum from kit design and manufacturing to clinical application. REV-MED works with partners across Asia, the Middle East, and Europe to expand the frontiers of personalized regenerative medicine, and continues to invest in R&D and quality innovation to lead the future of medical technology. At REV-MED, we don’t just develop medical devices—we develop technologies that help life go further. Better health. Longer life. Real healing—powered by REV-MED. For more information, please visit en.rev-med.co.kr
Noul
“Empowering Diagnostics Anywhere in the World with AI Technology!” Noul is an digital healthcare company committed to tackling global health challenges through innovative solutions. Its flagship product, miLab™, is the world’s first on-device AI diagnostic solution, enabling automated blood and cancer diagnostics in just 15 minutes.
LCS Biotech
LCS Biotech is a R&D oriented company specialized in Ecoceramide, Proceramide and other innovative products based on biotechnology. LCS Biotech has been recognized to have unique expertise in bioactive lipids, especially sphingolipids and phospholipids for the last 10 more years. Our service ranges are providing market leading concept and project based development, such as customized ceramide as a solution. We committed ourselves to support eco-friendly process and scientifically proven efficacy. | Since 2007, LCS Biotech is a R&D oriented company located in Korea, and has unique expertise in bioactive lipids, especially sphingolipids and ceramides. As a world Leader in Ceramide Science and technology, LCS Biotech offers innovative and environmentally friendly ceramides backed by scientifically validated efficacy data, and is dedicated to supporting sustainable practices.
iN Therapeutics
## Overview ## iN Therapeutics is a clinical-stage South Korean biotechnology company dedicated to discovering and developing “First-in-Class” and “Best-in-Class” ion channel modulators. As a spin-off from Daewoong Pharmaceutical, we combine the agility of a biotech with the robust R&D infrastructure of a major pharmaceutical group. Our mission is to address significant unmet medical needs in Central Nervous System (CNS) and chronic pain disorders by delivering highly selective and safe ion channel therapies. ## Core Technology: The VITVO™ Platform ## At the heart of our innovation is VITVO™, our proprietary ion channel drug discovery platform. Historically, ion channel drug discovery has been hindered by the “efficacy-toxicity trade-off” due to poor subtype selectivity. VITVO™ overcomes this challenge through: • Proprietary Compound Library: A vast collection of ion channel-specific chemical scaffolds. • Advanced Electrophysiology: High-throughput screening (HTS) and sophisticated patching techniques that ensure high-fidelity in vitro-in vivo correlation. • Precision Targeting: Achieving unprecedented subtype selectivity (e.g., Nav1.7 vs. Nav1.5) to eliminate off-target side effects and maximize the safety margin. ## Key Pipeline Assets ## iN Therapeutics is advancing a diverse and robust pipeline of innovative therapies: 1. Aneratrigine (iN1011-N17) | Target: Nav1.7 (Non-opioid Analgesic) • Indication: Pain • Achievement: Successfully demonstrated exceptional selectivity and efficacy, leading to a $500+ million global licensing deal. This asset represents our ability to tackle high-difficulty targets and translate them into significant commercial value. 2. iN3011-K23 | Target: Kv7.2/7.3 Activator • Indication: Focal Epilepsy and Neuropathic Pain. • Competitive Edge: Unlike traditional anti-seizure medications that often cause drowsiness through GABAergic pathways, Aneratrigine offers a “Clean Profile.” It focuses solely on Kv7.2/7.3 channels, aiming for superior efficacy without the typical CNS side effects, thereby significantly improving patient quality of life. 3. iN4011-KC2 | Target: KCC2 (First-in-Class) • Indication: Epilepsies and Neurological Disorders. • Vision: Targeting the fundamental mechanism of chloride homeostasis in the brain to treat refractory neurological conditions. 4. Nav 1.2/1.6 Inhibitor | Target: Dual Selective Inhibition • Indication: Epilepsy. • Strategy: Developing highly selective inhibitors to treat genetic epilepsies while avoiding cardiac and peripheral toxicities. ## Partnership & Track Record ## We are a proven partner in the global licensing market. Our landmark $500+M deal for the Nav1.7 program highlights our excellence in asset development and alliance management. We are actively seeking strategic partnerships for our preclinical-stage assets, including Kv7.2/7.3 Activator, and are open to collaborative research opportunities utilizing our VITVO™ platform. ## Vision for BIO USA 2026 ## At BIO USA 2026, iN Therapeutics seeks to engage with global pharmaceutical leaders, investors, and research institutions to discuss licensing-out opportunities, co-development strategies, and the future of ion channel-based medicine. We invite you to explore how our “Ion Channel Frontiers” are reshaping the landscape of CNS and Pain therapy.